Adma Biologics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Adma Biologics, Inc. - overview
Established
2004
Location
-, NJ-New Jersey, US
Primary Industry
Pharmaceuticals
About
ADMA Biologics is a biopharmaceutical company focused on developing and commercializing specialty biologic products, specifically targeting immunotherapy solutions for patients with primary immunodeficiency diseases and other immune-compromised conditions. Founded in 2004 in Ramsey, New Jersey, ADMA Biologics specializes in providing immunotherapy solutions. The company has undergone strategic developments to enhance its product offerings. The founder, Adam Grossman, has a history in the biotech sector, contributing to the evolution of the company.
In October 2013, ADMA Biologics raised USD 26. 5 mn through an IPO, marking a significant milestone as it launched 3. 35 million shares at USD 8. 5 per share.
The company has completed 7 deals to date, with the latest deal occurring in 2013. ADMA Biologics, Inc. specializes in the development and commercialization of specialty biologic products, primarily focusing on immunotherapy solutions for individuals with primary immunodeficiency diseases and other patients who are immune-compromised. The company's flagship offerings include ASCENIV™, BIVIGAM®, and Nabi-HB®, all of which are FDA-approved immune globulin products designed to provide critical immunological support to patients at risk of infections.
The proprietary microneutralization assay developed by ADMA allows for precise measurement of neutralizing antibody titers in plasma donor samples, enhancing the efficacy and safety of their products. ADMA's products are primarily marketed in the United States, catering to healthcare providers and facilities involved in the treatment of patients with compromised immune systems, thus addressing significant unmet medical needs in this patient population. In 2024, ADMA Biologics reported a total revenue of USD 426. 45 mn, alongside an EBITDA of USD 147.
03 mn, demonstrating strong financial performance. Business transactions typically occur through direct sales to hospitals, clinics, and specialty pharmacies, which serve as the primary distribution channels. The revenue structure is influenced by the sales of key products such as ASCENIV™, which are priced according to competitive market standards and reflect the specialized nature of the therapies provided. The revenue growth is supported by robust production capabilities and innovative yield enhancement processes that aim to improve efficiency and scalability in manufacturing.
ADMA Biologics is focused on expanding its product portfolio and market presence. The company is currently developing new immunotherapy products aimed at addressing additional immunodeficiency disorders, with potential launches slated for 2025. Additionally, ADMA plans to expand its market reach into Europe and Asia by 2026, capitalizing on rising demand for biologic therapies in these regions. The funding raised in October 2013 will support these initiatives, providing necessary resources for research and development, as well as market entry strategies.
Current Investors
Burrill & Company, Hercules Capital, Aisling Capital
Primary Industry
Pharmaceuticals
Sub Industries
Medical Devices & Equipment, Pharmaceutical Research & Development
Website
www.admabiologics.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Adma Biologics, Inc. - timeline of key events
Adma Biologics, Inc. - financials
| Fiscal Year Ended | Jun 30, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | 1,118,118 | 3,067,577 | 5,915,545 | 7,177,633 | 10,661,037 | 22,760,560 | 16,985,290 | 29,349,083 | 42,219,783 | 80,942,625 | 154,079,692 | - | - | - |
| % Revenue Growth (YoY) | - | - | - | 92.8% | 21.3% | 48.5% | 113.5% | (25.4%) | 72.8% | 43.9% | 91.7% | 90.4% | - | - | - |
| EBITDA (USD) | - | (7,721,567) | (14,684,930) | (15,587,263) | (14,777,984) | (16,326,710) | (35,978,962) | (55,881,219) | (37,128,665) | (59,332,991) | (51,123,700) | (29,992,876) | - | - | - |
| Operating Income (USD) | (26,464) | (7,909,169) | (15,042,431) | (16,018,533) | (15,513,807) | (17,330,395) | (39,309,996) | (60,288,944) | (41,424,327) | (64,914,877) | (58,373,741) | (39,365,080) | - | - | - |
| Operating Margin | - | (707.4%) | (490.4%) | (270.8%) | (216.1%) | (162.6%) | (172.7%) | (354.9%) | (141.1%) | (153.8%) | (72.1%) | (25.5%) | - | - | - |
| % EBITDA Margin | - | (690.6%) | (478.7%) | (263.5%) | (205.9%) | (153.1%) | (158.1%) | (329.0%) | (126.5%) | (140.5%) | (63.2%) | (19.5%) | - | - | - |
| NET Income (USD) | (26,460) | (7,301,313) | (15,527,246) | (16,813,163) | (17,969,930) | (19,515,151) | (43,758,975) | (65,743,445) | (48,279,317) | (75,748,548) | (71,647,618) | (65,903,950) | - | - | - |
| % Net Margin | - | (653.0%) | (506.2%) | (284.2%) | (250.4%) | (183.1%) | (192.3%) | (387.1%) | (164.5%) | (179.4%) | (88.5%) | (42.8%) | - | - | - |
Adma Biologics, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Debt | Completed | Adma Biologics, Inc. | - | ||||||||
| Private Debt | Completed | Adma Biologics, Inc. | - | ||||||||
| Private Debt | Completed | Adma Biologics, Inc. | - | ||||||||
| IPO | Completed | Adma Biologics, Inc. | - | ||||||||
| Venture Debt | Completed | Adma Biologics, Inc. | - |
Displaying 1 - 5 of 7
Adma Biologics, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.